Evolutionary medicine

Evolutionary medicine, also called Darwinian medicine, is the application of evolutionary biology to the understanding of human health and disease. Its central premise is that many aspects of human vulnerability to disease — from our susceptibility to infections and cancers to the prevalence of obesity, diabetes, and autoimmune disorders — cannot be fully understood without considering the evolutionary processes that shaped the human body over millions of years.^{1, 2} Rather than simply asking how a disease operates (the proximate, mechanistic question), evolutionary medicine also asks why the body is designed in ways that leave it vulnerable (the ultimate, evolutionary question). These two perspectives are complementary, and together they can inform more effective strategies for prevention and treatment.¹

Mismatch diseases

Many chronic diseases of modern industrialised societies are mismatch diseases: conditions that arise because the human body, shaped by natural selection in environments very different from those in which most people now live, is poorly adapted to modern diets, activity levels, and lifestyles. The human genome has changed relatively little in the approximately 10,000 years since the agricultural revolution, but the human environment has changed dramatically, creating a mismatch between evolved biology and current conditions.⁸

Type 2 diabetes illustrates this concept. Neel's "thrifty genotype" hypothesis, proposed in 1962, suggested that genes promoting efficient fat storage and insulin resistance would have been advantageous in ancestral environments characterised by unpredictable food availability, allowing individuals to store energy during periods of abundance and survive periods of famine.⁷ In modern environments of caloric surplus and physical inactivity, however, these same genetic variants promote obesity, insulin resistance, and eventually type 2 diabetes. While the specific thrifty genotype hypothesis has been refined and debated since its original formulation, the broader mismatch framework — that metabolic diseases reflect a disconnection between evolved physiology and modern environments — is widely accepted.⁸

Similar mismatch explanations have been proposed for the modern epidemics of cardiovascular disease (ancestral selection for salt retention and inflammatory responses now operating in an environment of dietary excess), myopia (near-work-intensive environments versus the outdoor settings in which human visual development evolved), and lower back pain (bipedal locomotion was a compromise adaptation, and the modern sedentary lifestyle exacerbates its mechanical limitations).^{1, 2}

The hygiene hypothesis and immune mismatch

The dramatic rise in allergies, asthma, and autoimmune diseases in industrialised countries over the past century has been attributed in part to an immune mismatch. The hygiene hypothesis proposes that the human immune system evolved in the context of chronic helminth (parasitic worm) infections and diverse microbial exposures that are now largely absent in sanitised modern environments. The regulatory arm of the immune system, which evolved to prevent excessive inflammatory responses to ubiquitous parasites and commensals, is left underemployed in hygienic environments and may become dysregulated, leading to inappropriate immune responses against harmless antigens (allergies) or self-antigens (autoimmunity).¹³

Epidemiological evidence supports this framework. The prevalence of allergic and autoimmune diseases is inversely correlated with the prevalence of helminth infections across populations, and experimental helminth infection has shown therapeutic promise in clinical trials for inflammatory bowel disease and multiple sclerosis.¹³ The evolutionary perspective suggests that some inflammatory diseases may result not from a malfunctioning immune system but from a normally functioning immune system operating in an environment for which it was not designed.^{1, 13}

Antibiotic resistance as evolution in action

Antibiotic resistance is one of the most visible and consequential examples of evolution by natural selection occurring in real time. When a bacterial population is exposed to an antibiotic, individuals carrying resistance genes — whether acquired by mutation or horizontal gene transfer — survive and reproduce while susceptible individuals are killed, rapidly shifting the population composition toward resistance.^{3, 4}

The mechanisms of resistance are diverse and include enzymatic degradation of the antibiotic (such as beta-lactamases that cleave penicillin), modification of the antibiotic's molecular target (such as altered ribosomes that are not inhibited by macrolides), active efflux pumps that expel the antibiotic from the cell, and reduced permeability of the cell envelope.⁴ Critically, many resistance genes predate the clinical use of antibiotics: they evolved in soil-dwelling bacteria as a defence against the antimicrobial compounds produced by competing microorganisms, and their mobilisation into pathogenic bacteria through horizontal gene transfer represents a case of pre-existing genetic variation being selected for in a novel environment.³

The evolutionary framework has direct implications for antibiotic stewardship. Evolutionary models predict that antibiotic cycling (rotating different antibiotics over time), combination therapy (using multiple antibiotics simultaneously to reduce the probability of resistance to all drugs), and reducing unnecessary antibiotic use will slow the evolution of resistance by decreasing the selective advantage of resistant genotypes.³

The evolution of virulence

Understanding why some pathogens are highly virulent (causing severe disease) while others are benign requires an evolutionary perspective. The traditional view — that pathogens inevitably evolve toward reduced virulence because killing the host is disadvantageous — has been replaced by a more nuanced evolutionary framework. The trade-off hypothesis proposes that virulence is an indirect consequence of pathogen replication and transmission: a pathogen that replicates aggressively within the host may cause more damage (higher virulence) but also produce more transmissible propagules, while a pathogen that replicates cautiously may cause less damage but transmit less efficiently.¹⁴ Natural selection optimises the balance between these competing pressures, and the optimal virulence depends on the pathogen's mode of transmission, the duration of infection, and the availability of susceptible hosts.¹⁴

This framework explains why vector-borne diseases (transmitted by mosquitoes, ticks, etc.) tend to be more virulent than directly transmitted diseases: because the pathogen does not depend on host mobility for transmission, it can afford to incapacitate or even kill the host without losing transmission opportunities. It also explains why hospital-acquired infections tend to be caused by more virulent strains than community-acquired infections, because the high density of susceptible hosts in hospitals relaxes the selection against virulence.^{14, 2}

Cancer as somatic evolution

Cancer is fundamentally an evolutionary process occurring within the body. The clonal evolution model, first articulated by Peter Nowell in 1976, proposes that cancer arises through the sequential accumulation of somatic mutations in a single cell lineage, with each mutation conferring a selective growth advantage that allows the mutant clone to expand at the expense of normal cells.⁶ The hallmarks of cancer — self-sufficient growth signalling, insensitivity to anti-growth signals, evasion of apoptosis, limitless replicative potential, sustained angiogenesis, and tissue invasion — are the phenotypic outcomes of this somatic evolutionary process.¹⁵

The evolutionary perspective explains several clinically important features of cancer. Tumour heterogeneity — the presence of genetically distinct subclones within a single tumour — is a natural consequence of ongoing mutation and clonal selection, analogous to genetic diversity within a population of organisms. Drug resistance in cancer follows the same evolutionary logic as antibiotic resistance: chemotherapy selects for pre-existing or newly arising resistant clones, which then proliferate and dominate the tumour population.^{5, 16}

Evolutionary insights have begun to inform cancer treatment strategies. Adaptive therapy, proposed by Gatenby and colleagues, deliberately modulates drug doses to maintain a population of drug-sensitive cells that competitively suppress drug-resistant cells, rather than attempting to eliminate all cancer cells with maximum-dose chemotherapy (which selects strongly for resistance). This approach, inspired by evolutionary principles of competitive exclusion, has shown promise in clinical trials for metastatic prostate cancer.^{5, 16}

Evolutionary trade-offs and disease susceptibility

Many genetic conditions that appear purely deleterious become explicable when their evolutionary history is considered. Sickle cell disease, caused by a point mutation in the beta-globin gene, is one of the most well-known examples. Individuals homozygous for the sickle cell allele (HbS/HbS) suffer severe anaemia, but heterozygous carriers (HbA/HbS) have a significant survival advantage in malaria-endemic regions because the sickling of red blood cells infected with Plasmodium falciparum impairs the parasite's development. Allison demonstrated in 1954 that the geographic distribution of the sickle cell allele closely matches the historical distribution of malaria, confirming that balancing selection maintains the allele at appreciable frequencies despite its severe homozygous phenotype.^{11, 12}

Similar trade-offs have been proposed for other genetic diseases. Cystic fibrosis heterozygotes may have historically been more resistant to cholera or typhoid fever. Hemochromatosis heterozygotes may have had advantages in iron-poor diets. The persistence of these disease alleles at frequencies higher than would be expected from mutation-selection balance alone suggests that heterozygote advantage has maintained them over evolutionary time, even though they cause severe disease in homozygotes.^{1, 2}

The evolutionary biology of ageing

Why do organisms age and die? Evolutionary biology provides two complementary explanations. Medawar's mutation accumulation theory proposes that the force of natural selection declines with age, because organisms in the wild rarely survive long enough for late-acting deleterious mutations to be exposed to selection. Such mutations therefore accumulate in the genome over evolutionary time, producing the degenerative changes we recognise as ageing.¹⁰

Williams' antagonistic pleiotropy theory extends this logic by proposing that some genes have beneficial effects early in life but harmful effects late in life, and that natural selection favours such genes because the early-life benefits outweigh the late-life costs (since few individuals survive to experience the costs in natural populations).⁹ Kirkwood's disposable soma theory reframes the problem in terms of resource allocation: organisms have limited energy budgets, and natural selection favours investment in reproduction over somatic maintenance when the probability of extrinsic mortality (predation, infection, accident) is high, because individuals in dangerous environments are unlikely to live long enough to benefit from expensive DNA repair and antioxidant defences.¹⁷

These theories make testable predictions. Species with low extrinsic mortality (such as birds, bats, and turtles) should evolve slower rates of ageing than species with high extrinsic mortality, because the selective advantage of somatic maintenance is greater when individuals have a reasonable probability of surviving to old age. Comparative studies across vertebrates have broadly confirmed this prediction, supporting the evolutionary framework for understanding senescence.^{2, 17}